These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24486221)

  • 1. Mechanism-based treatment in tuberous sclerosis complex.
    Jülich K; Sahin M
    Pediatr Neurol; 2014 Apr; 50(4):290-6. PubMed ID: 24486221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
    Mizuguchi M; Ohsawa M; Kashii H; Sato A
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis: a review of the past, present, and future.
    Uysal SP; Şahin M
    Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
    Davis PE; Peters JM; Krueger DA; Sahin M
    Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
    Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
    Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
    Nguyen LH; Mahadeo T; Bordey A
    J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
    Tee AR; Sampson JR; Pal DK; Bateman JM
    Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
    Zhang B; McDaniel SS; Rensing NR; Wong M
    PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
    Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
    J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberous sclerosis complex.
    Hasbani DM; Crino PB
    Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
    Ehninger D; Silva AJ
    Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.